The effects of SGLT2 inhibitors on atrial fibrillation recurrence and cardiac function after catheter ablation in patients with atrial fibrillation and heart failure: a retrospective cohort study and meta-analysis - Summary - MDSpire
Advertisement
The effects of SGLT2 inhibitors on atrial fibrillation recurrence and cardiac function after catheter ablation in patients with atrial fibrillation and heart failure: a retrospective cohort study and meta-analysis
To evaluate the effect of SGLT2 inhibitors on the recurrence of postoperative atrial fibrillation and cardiac performance in patients with atrial fibrillation and heart failure undergoing catheter ablation.
Key Findings:
SGLT2i group had a lower recurrence rate of atrial arrhythmia (13.25% vs. 25.88%, P = 0.039).
SGLT2i administration was an independent predictor of reduced atrial arrhythmia recurrence (HR 0.45, 95% CI: 0.22–0.94, P = 0.033).
At 12-month follow-up, SGLT2i group showed reduced left atrial diameter and increased left ventricular ejection fraction (LA: 37.37 ± 4.25 mm vs. 39.25 ± 6.22 mm, P = 0.024; LVEF: 62.06 ± 11.39% vs. 58.89 ± 7.98%, P = 0.039).
Meta-analysis indicated SGLT2i significantly reduced atrial arrhythmia recurrence (RR = 0.59, 95% CI: 0.51–0.69, P < 0.001) and all-cause mortality (RR: 0.66, 95% CI: 0.48–0.91, P = 0.011).
Interpretation:
SGLT2 inhibitors are associated with lower rates of AF recurrence and improved cardiac function in patients with AF and HF post-ablation, highlighting their potential role in clinical management.
Limitations:
Retrospective design may introduce bias and limit causal inferences.
Limited generalizability due to single-center data collection and potential confounding factors.
Conclusion:
SGLT2 inhibitors are beneficial in reducing AF recurrence and enhancing cardiac function in patients with AF and HF after catheter ablation, with implications for lower all-cause mortality risks and recommendations for further research.
The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.
